$14.99
0.79% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US74587B1017
Symbol
PLSE

Pulse Biosciences, Inc. Stock price

$14.99
-0.08 0.53% 1M
-2.88 16.12% 6M
-2.42 13.90% YTD
-2.11 12.34% 1Y
+13.67 1,035.61% 3Y
+5.57 59.13% 5Y
+10.82 259.47% 10Y
+10.82 259.47% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-0.12 0.79%

Key metrics

Basic
Market capitalization
$1.0b
Enterprise Value
$902.2m
Net debt
positive
Cash
$106.4m
Shares outstanding
67.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 791.0
EV/Sales
- | 707.6
EV/FCF
negative
P/B
9.7
Financial Health
Equity Ratio
86.7%
Return on Equity
-46.7%
ROCE
-64.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $1.3m
EBITDA
$-71.1m | -
EBIT
$-72.2m | $-85.0m
Net Income
$-68.0m | $-80.3m
Free Cash Flow
$-44.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-58.3% | -
EBIT
-56.6% | -56.3%
Net Income
-54.5% | -49.8%
Free Cash Flow
-25.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -6,297.4%
Free Cash Flow
-
More
EPS
$-1.0
FCF per Share
$-0.7
Short interest
16.5%
Employees
75
Rev per Employee
$0.0
Show more

Is Pulse Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Pulse Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Pulse Biosciences, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Pulse Biosciences, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Pulse Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
82% 82%
-
- Research and Development Expense 41 41
39% 39%
-
-71 -71
58% 58%
-
- Depreciation and Amortization 1.14 1.14
5% 5%
-
EBIT (Operating Income) EBIT -72 -72
57% 57%
-
Net Profit -68 -68
55% 55%
-

In millions USD.

Don't miss a Thing! We will send you all news about Pulse Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pulse Biosciences, Inc. Stock News

Neutral
Business Wire
2 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the first successful procedures in a multicenter IRB-approved study using Pulse Biosciences' nsPFA™ Percutaneous Electrode System for the treatment of benign thyroid nodules (BTNs). “Succ...
Neutral
Business Wire
9 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced a new publication in the Journal Thyroid. The First-in-Human Clinical feasibility study demonstrates the effectiveness of ablation of benign thyroid nodules using nsPFA energy. The study ...
Neutral
Seeking Alpha
22 days ago
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Jon Skinner - Chief Financial Officer Paul Arthur LaViolette - President, CEO, Principal Executive Officer, Principal Financial Officer & Co- Chairman of the Board Conference Call Participants Anthony Charles Petrone - Mizuho Securities USA LLC, Research Division Joshua Thomas...
More Pulse Biosciences, Inc. News

Company Profile

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.

Head office United States
CEO Paul LaViolette
Employees 75
Founded 2014
Website www.pulsebiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today